Why Farbe Firma is the Top Manufacturer of Furosemide Injection
- Maulik Sudani
- May 26
- 6 min read
Last Updated: May 26, 2026
TL;DR: Furosemide Injection — a sterile, ready-to-use parenteral solution of furosemide, supplied most commonly as 10 mg/mL in 2 mL and 4 mL ampoules (20 mg and 40 mg) and 25 mL multi-dose vials (250 mg) — is the rapid-onset loop diuretic of choice in acute pulmonary oedema, congestive heart failure, hypertensive crises and oliguric renal failure. Within minutes of intravenous administration it produces a potent natriuresis and diuresis that takes pressure off the lungs and the circulation. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Furosemide Injection at our Gujarat, India facility and supplies it to hospital tenders, critical-care and emergency programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Loop diuretic — Furosemide Injection inhibits the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle, producing rapid and powerful diuresis with significant natriuresis and chloruresis. The parenteral route delivers onset within 5 minutes, making it indispensable in acute pulmonary oedema, decompensated heart failure, hypertensive emergencies and acute renal failure where the oral route is too slow or unreliable.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule and vial filling lines, dedicated light-protected handling for the photosensitive furosemide molecule and validated terminal sterilisation with full container-closure integrity verification.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Furosemide Injection Demands a Premium Manufacturer
Furosemide Injection is a workhorse of acute hospital medicine. When a patient arrives breathless and hypoxic with pulmonary oedema, when a heart-failure decompensation refuses to respond to oral diuretics, when a hypertensive emergency needs immediate volume offloading or when an oliguric kidney needs to be challenged for a diuretic response, intravenous furosemide is the drug the clinician reaches for. Onset within 5 minutes, a clean and well-understood mechanism at the loop of Henle, and a long safety record across decades of use make it indispensable across emergency departments, cardiology and intensive-care units, dialysis programmes and surgical recovery wards. Because it is given to physiologically unstable patients — often with one-shot, time-critical doses — the consequences of a sub-potent, contaminated or precipitated ampoule are immediate.
That clinical context places real demands on the manufacturer. Furosemide is a weakly acidic, photosensitive molecule that needs careful pH control around 8 to 9 to stay in solution and protection from light through its entire shelf life. The solution must be crystal clear, free of visible and sub-visible particulate, reliably sterile and endotoxin-free, and stable across the long, hot supply chains of the emerging-market hospital systems where Farbe Firma's customers operate. It must also be compatible with the dextrose and saline infusions and the central-line setups it will share. Choosing a Furosemide Injection manufacturer that treats pH and photostability control, particulate-free filling and validated stability as core engineering disciplines is what keeps a hospital's most acute prescriptions safe.
What Sets a World-Class Furosemide Injection Manufacturer Apart
A world-class manufacturer of Furosemide Injection invests in three areas that weaker suppliers underfund: photostable formulation and packaging, precision pH and assay control, and a sterility and particulate programme built for an alkaline, photosensitive small-volume parenteral. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade furosemide sourced from qualified, audited API manufacturers, with full impurity profiling and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The solution pH is tightly controlled, in-process assay confirms label strength, and the filling is performed under ISO Class 5 air in amber glass or light-protective secondary packaging to shield against UV-driven degradation. Container-closure integrity is verified, and stability is tracked under ICH Q1A long-term and accelerated conditions as well as ICH Q1B photostability protocols. World-class plants also keep multi-dose vial presentations to a rigorous preservative-efficacy specification, because real-world repeated needle entries are part of the product's working life on a busy ward.
Quality Systems Behind Every Furosemide Injection
Every Farbe Firma Furosemide Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substance and degradation-product profiling, pH, osmolality, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification appropriate to the ampoule or vial format. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Furosemide Injection they buy today will still meet specification when it reaches the patient months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Furosemide Injection Manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across critical-care, cardiology, emergency-medicine, anti-infective and supportive-care categories. For Furosemide Injection specifically, we supply 10 mg/mL in 2 mL and 4 mL clear or amber glass ampoules (20 mg and 40 mg strengths) and 25 mL multi-dose vials (250 mg), with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Furosemide Injection at tender scale — and emergency-medicine procurement is almost always high-volume and time-critical — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, photostability strategy, particulate control, sterilisation, container-closure and stability choices in real detail. For a drug given to unstable patients in time-critical doses, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Furosemide Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Furosemide Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems and validated environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Furosemide Injection do you supply?
Our standard presentations are 10 mg/mL in 2 mL ampoules (20 mg) and 4 mL ampoules (40 mg) for single-dose use, and 25 mL multi-dose vials (250 mg) for higher-dose intravenous-infusion regimens. Amber or clear glass with light-protective secondary packaging, custom fill volumes, container formats and country-specific pack configurations are available under contract manufacturing agreements — share your specification and our technical team will quote within 48 hours.
Can Farbe Firma support country-specific registrations for Furosemide Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the potency and photostability of Furosemide Injection?
We control the pH around 8 to 9 to keep furosemide in stable solution, run HPLC assay and related-substances testing on every batch, package in amber glass or light-protective secondary cartons, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability. Endotoxin, sterility and container-closure integrity are confirmed on every batch.
What is the minimum order quantity for Furosemide Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For both single-dose ampoule and multi-dose vial presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments